Solid Biosciences (SLDB) Free Cash Flow (2017 - 2026)

Solid Biosciences has reported Free Cash Flow for 10 years, with the latest figure at -$47.4 million in Q1 2026.

• Quarterly Free Cash Flow fell 48.22% year-over-year to -$47.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$171.8 million (down 60.07% YoY) and the FY2025 annual result came in at -$156.3 million, down 55.3% from the prior year.
• Free Cash Flow climbed to -$47.4 million in Q1 2026 per SLDB's latest filing, from -$53.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$17.0 million in Q2 2022 and troughed at -$53.0 million in Q4 2025.
• A 5-year average of -$29.3 million and a median of -$27.4 million in 2022 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow jumped 35.79% in 2023, then sank 75.17% in 2025.
• Over 5 years, Free Cash Flow stood at -$34.8 million in 2022, then jumped by 35.79% to -$22.3 million in 2023, then tumbled by 35.48% to -$30.3 million in 2024, then tumbled by 75.17% to -$53.0 million in 2025, then rose by 10.6% to -$47.4 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$47.4 million, -$53.0 million, and -$34.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.